Active Ingredient History

  • Now
Insulin glargine, a long-acting form of insulin, was marketed under the brand name LANTUS. Lantus is indicated for the treatment of adult and pediatric patients with type 1 diabetes mellitus or adult patients with type 2 diabetes mellitus who require basal (long-acting) insulin for the control of hyperglycemia. The primary activity of insulin glargine is regulation of glucose metabolism. It lowers blood glucose levels by stimulating peripheral glucose uptake, especially by skeletal muscle and fat, and by inhibiting hepatic glucose production. The off-label use of insulin glargine is the treatment type 2 diabetes in children and the treatment of gestational diabetes.   NCATS

More Chemistry
  • Mechanisms of Action:
  • Multi-specific: No
  • Black Box: No
  • Availability: Prescription Only
  • Delivery Methods: Parenteral
  • Pro Drug: No

Drug Pricing (per unit)

United States

$5.9850 - $82.9579


$26.4300 - $60.8998
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Combination drugs

( insulin glargine (toujeo), lixisenatide (adlyxin) - other name: insulin glargine and lixisenatide )
abasaglar | abasaglar kwikpen | glargine insulin | hoe-71gt | hoe-901 | iglarlixi | ins lantus | ins lantus opticlik | ins lantus optiset | ins lantus solostar | insulin glargine | insulin glargine (genetical recombination) | insulin glargine / lixisenatide | insulin glargine (rdna origin) | insulin glargine recombinant | lantus | lantus solostar | ly2963016 | mk-1293 | sar161271 | toujeo


Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue